RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

被引：0
|
作者：
Chunyue Wang
Zhenlong Zhang
Yulan Sun
Song Wang
Mengmeng Wu
Qiuxiang Ou
Yang Xu
Zhiming Chen
Yang Shao
Hong Liu
Peifeng Hou
机构：
[1] Xiamen University,Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine
[2] Shengli Clinical Medical College of Fujian Medical University,Department of Thoracic Surgery
[3] Fujian Provincial Hospital,Department of Internal Medicine Division
[4] Shandong Cancer Hospital Affiliated to Shandong First Medical University,Department of Radiation Oncology
[5] Geneseeq Research Institute,Department of Medical Oncology
[6] Nanjing Geneseeq Technology Inc.,undefined
[7] Affiliated Hospital of Nantong University,undefined
[8] Qilu Hospital of Shandong University,undefined
[9] Fujian Medical University Union Hospital,undefined
来源：
Journal of Translational Medicine | / 20卷
关键词：
rearrangement; NSCLC; EGFR-TKI; Noncanonical ; fusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
    Enrico, Diego
    Lacroix, Ludovic
    Chen, Jeanne
    Rouleau, Etienne
    Scoazec, Jean-Yves
    Loriot, Yohann
    Tselikas, Lambros
    Jovelet, Cecile
    Planchard, David
    Gazzah, Anas
    Mezquita, Laura
    Ngo-Camus, Maud
    Michiels, Stefan
    Massard, Christophe
    Recondo, Gonzalo
    Facchinetti, Francesco
    Remon, Jordi
    Soria, Jean-Charles
    Andre, Fabrice
    Vassal, Gilles
    Friboulet, Luc
    Besse, Benjamin
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (02):
  • [22] Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
    Wang, Xiaochun
    Goldstein, David
    Crowe, Philip J.
    Yang, Jia-Lin
    ONCOTARGETS AND THERAPY, 2016, 9 : 5461 - 5473
  • [23] Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review
    Leporati, Rita
    Auclin, Edouard
    Morchon, Daniel
    Ferriol-Galmes, Miquel
    Laguna, Juan Carlos
    Gorria, Teresa
    Teixido, Cristina
    Aranzazu Amores, Maria
    Ambrosini, Paolo
    Isla, Dolores
    Lo Russo, Giuseppe
    Mezquita, Laura
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [24] EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer and the Role of Diabetes Mellitus and Metformin
    Cipriano, E.
    Magalhaes, H.
    Estevinho, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S622 - S622
  • [25] Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
    Rotow, J.
    Patel, J.
    Hanley, M.
    Yu, H.
    Goldman, J.
    Nechustan, H.
    Scheffler, M.
    Awad, M.
    Clifford, S.
    Santucci, A.
    Silva, L.
    Tupper, R.
    Oxnard, G.
    Kherani, J.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S230 - S230
  • [26] EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
    van Zandwijk, N.
    Mathy, A.
    Boerrigter, L.
    Ruijter, H.
    Tielen, I.
    de Jong, D.
    Baas, P.
    Burgers, S.
    Nederlof, P.
    ANNALS OF ONCOLOGY, 2007, 18 (01) : 99 - 103
  • [27] ROS1 fusions in Chinese patients with non-small-cell lung cancer
    Cai, W.
    Li, X.
    Su, C.
    Fan, L.
    Zheng, L.
    Fei, K.
    Zhou, C.
    Manegold, C.
    Schmid-Bindert, G.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1822 - 1827
  • [28] Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterations
    Wang, Yanhua
    Xu, Manyi
    Wang, Ke
    Hao, Yue
    Xu, Chunwei
    Song, Zhengbo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [29] Clinical Characteristics and Outcomes of EGFRPositive Non-Small Cell Lung Cancer with Acquired RET Fusions
    Kobayashi, T.
    Shinno, Y.
    Yamaguchi, Y.
    Matsumoto, Y.
    Okuma, Y.
    Yoshida, T.
    Goto, Y.
    Horinouchi, H.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S633 - S633
  • [30] Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
    Li, Yang
    Ni, Yunfeng
    Lv, Feng
    Shi, Yan
    Chen, Yedan
    Wu, Xiaoying
    Pang, Jiaohui
    Huang, Long
    Shao, Yang
    Wang, Tao
    Min, Jie
    Song, Yang
    BMC MEDICINE, 2025, 23 (01):
12345